Refine
Year of publication
Document Type
- Doctoral Thesis (3270)
- Article (1921)
- Book (24)
- Conference Proceeding (17)
- Course Material (6)
- Report (6)
- Final Thesis (5)
- Part of a Book (1)
- Habilitation (1)
Language
- English (2679)
- German (2568)
- Multiple languages (4)
Is part of the Bibliography
- no (5251)
Keywords
- - (1171)
- Sepsis (83)
- Staphylococcus aureus (59)
- Plasma (45)
- Diabetes mellitus (37)
- Epidemiologie (37)
- SHIP (34)
- Proteomanalyse (33)
- Depression (31)
- proteomics (31)
Institute
- Institut für Biochemie (280)
- Institut für Physik (274)
- Kliniken und Polikliniken für Innere Medizin (265)
- Institut für Pharmazie (219)
- Abteilung für Mikrobiologie und Molekularbiologie (206)
- Institut für Community Medicine (200)
- Institut für Hygiene und Umweltmedizin (151)
- Zoologisches Institut und Museum (150)
- Institut für Botanik und Landschaftsökologie & Botanischer Garten (148)
- Institut für Geographie und Geologie (146)
Publisher
- MDPI (568)
- Frontiers Media S.A. (364)
- Wiley (221)
- S. Karger AG (157)
- Springer Nature (136)
- IOP Publishing (75)
- De Gruyter (61)
- BioMed Central (BMC) (59)
- SAGE Publications (49)
- Nature Publishing Group (39)
Simple Summary
The treatment of high-risk neuroblastoma patients with anti-GD2 antibodies has improved survival, and it is an established treatment strategy; however, many patients still experience a late relapse. One disadvantage of passive immunotherapy is the absence of a memory response. Therefore, developing an active immunotherapy leading to a sustained immune response may provide a solution and prevent the occurrence of late relapses following anti-GD2 antibody therapy. Here, we describe the first-in-man compassionate use of the ganglidiomab vaccine following passive immunotherapy with an anti-GD2 antibody (dinutuximab beta) in seven neuroblastoma patients. The vaccine was well-tolerated, and all patients not pre-treated by haploidentical transplantation developed vaccine-specific immune responses.
Abstract
(1) Background: High-risk neuroblastoma (HR-NB) is associated with a poor prognosis despite a multimodal high-intensity treatment regimen, including immunotherapy with anti-GD2 monoclonal antibodies (mAb). Here, we investigated the effects of an anti-idiotypic vaccine based on the mAb ganglidiomab that structurally mimics GD2. (2) Methods: Patients with HR-NB treated with anti-GD2 mAb dinutuximab beta and who achieved complete remission after frontline or salvage therapy were offered the vaccine (0.5 mg ganglidiomab adsorbed to Alhydrogel®). Side effects (CTCAE v4.03) and immune responses were determined on each visit. We also evaluated the time to relapse or progression until the last follow-up. (3) Results: Seven HR-NB patients (five frontlines, two relapsed) received 6–22 subcutaneous injections every two weeks. Six of the seven patients showed an immune response. The non-responding patient had a haploidentical stem cell transplantation as part of the previous treatment. No fever, pain, neuropathy, or toxicities ≥ grade 3 occurred during or post-treatment. All immunized patients did not experience relapses or progressions of their neuroblastoma. (4) Conclusions: This is the first-in-man use of the ganglidiomab vaccine, which was well-tolerated, and all patients not pre-treated by haploidentical transplantation developed vaccine-specific immune responses. These findings provide an important basis for the design of prospective clinical trials.